California Public Employees Retirement System Has $169.03 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

California Public Employees Retirement System raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 218,772 shares of the biopharmaceutical company’s stock after buying an additional 17,682 shares during the quarter. California Public Employees Retirement System’s holdings in Regeneron Pharmaceuticals were worth $169,032,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Insigneo Advisory Services LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after acquiring an additional 13 shares during the period. Guardian Wealth Advisors LLC NC increased its stake in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 14 shares during the last quarter. TD Private Client Wealth LLC increased its stake in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 15 shares during the last quarter. MCF Advisors LLC raised its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares in the last quarter. Finally, Boyd Watterson Asset Management LLC OH raised its position in Regeneron Pharmaceuticals by 1.4% during the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 15 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Multiple law firms announced or promoted securities class-action activity tied to REGN, including a newly filed class action and related investor deadline notices. These developments can weigh on sentiment because they highlight alleged disclosure issues and raise the risk of legal costs or settlement uncertainty. Article: Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
• Negative Sentiment: Additional reminders from Faruqi & Faruqi, Robbins LLP, Levi & Korsinsky, and Bragar Eagel & Squire kept the lawsuit story in focus, reinforcing legal overhang for shareholders. Article: REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.
• Neutral Sentiment: A market commentary piece said Regeneron has rebounded and may still look undervalued, but also questioned whether the upside is already reflected in the shares, making the stock’s near-term direction less clear. Article: Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
• Neutral Sentiment: Brokerage coverage cited by American Banking News said REGN carries a “Moderate Buy” consensus, which supports the long-term outlook but is less likely to move the stock immediately than the litigation headlines. Article: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $676.69 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The firm has a market capitalization of $71.54 billion, a P/E ratio of 16.49, a P/E/G ratio of 1.50 and a beta of 0.24. The company’s 50 day moving average price is $640.99 and its two-hundred day moving average price is $718.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $8.22 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on REGN. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $787.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.